HK63789A - Solid medicament formulation containing nifedipine - Google Patents

Solid medicament formulation containing nifedipine

Info

Publication number
HK63789A
HK63789A HK637/89A HK63789A HK63789A HK 63789 A HK63789 A HK 63789A HK 637/89 A HK637/89 A HK 637/89A HK 63789 A HK63789 A HK 63789A HK 63789 A HK63789 A HK 63789A
Authority
HK
Hong Kong
Prior art keywords
nifedipine
medicament formulation
formulation containing
solid medicament
containing nifedipine
Prior art date
Application number
HK637/89A
Other languages
English (en)
Inventor
Ahmed Hegasy
Roland Rupp
Klaus-Dieter Ramsch
Helmut Luchtenberg
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6199643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK63789(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HK63789A publication Critical patent/HK63789A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
HK637/89A 1983-05-21 1989-08-10 Solid medicament formulation containing nifedipine HK63789A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833318649 DE3318649A1 (de) 1983-05-21 1983-05-21 Zweiphasenformulierung

Publications (1)

Publication Number Publication Date
HK63789A true HK63789A (en) 1989-08-18

Family

ID=6199643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK637/89A HK63789A (en) 1983-05-21 1989-08-10 Solid medicament formulation containing nifedipine

Country Status (29)

Country Link
US (1) US4562069A (el)
EP (1) EP0126379B1 (el)
JP (1) JPS59222475A (el)
AT (2) ATE42198T1 (el)
AU (1) AU564263B2 (el)
BE (1) BE899691A (el)
CA (1) CA1228550A (el)
CH (1) CH658190A5 (el)
CS (1) CS250663B2 (el)
DD (1) DD222495A5 (el)
DE (2) DE3318649A1 (el)
DK (1) DK163278C (el)
ES (1) ES532515A0 (el)
FI (1) FI82376C (el)
FR (1) FR2550092B1 (el)
GB (1) GB2139892B (el)
GR (1) GR82018B (el)
HK (1) HK63789A (el)
HU (1) HU193287B (el)
IL (1) IL71871A (el)
IT (1) IT1218848B (el)
KE (1) KE3889A (el)
NO (1) NO164817C (el)
NZ (1) NZ208214A (el)
PH (1) PH21989A (el)
PL (1) PL142890B1 (el)
PT (1) PT78611B (el)
SG (1) SG36089G (el)
ZA (1) ZA843769B (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
EP0159604B1 (en) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
DE4130173A1 (de) * 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
JP3148256B2 (ja) 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
EP0852141A1 (en) * 1996-08-16 1998-07-08 J.B. Chemicals & Pharmaceuticals Ltd. Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
IN186245B (el) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
DE60038536T2 (de) * 1999-09-30 2009-06-10 Penwest Pharmaceuticals Co. Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7429238B2 (en) * 2001-10-15 2008-09-30 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
EP2755637B1 (en) * 2011-09-13 2020-08-12 ISP Investments LLC Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
US20130259931A1 (en) * 2012-03-30 2013-10-03 Bandi Parthasaradhi Reddy Oral pharmaceutical compositions of nebivolol and process for their preparation
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
JPS5446837A (en) * 1977-09-19 1979-04-13 Kanebo Ltd Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same
ATE5852T1 (de) * 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5668619A (en) * 1980-10-09 1981-06-09 Yamanouchi Pharmaceut Co Ltd Nifedipine-containing solid composition
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS57167911A (en) * 1981-04-09 1982-10-16 Kyoto Yakuhin Kogyo Kk Liquid pharmaceutical of nifedipine
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
DE3142853A1 (de) * 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung
JPS5877811A (ja) * 1981-11-04 1983-05-11 Kanebo Ltd 安定な易吸収性ニフエジピン製剤の製法

Also Published As

Publication number Publication date
ZA843769B (en) 1984-12-24
NO841838L (no) 1984-11-22
NO164817C (no) 1990-12-19
GR82018B (el) 1984-12-12
DK163278C (da) 1992-09-07
FI841995A0 (fi) 1984-05-17
US4562069A (en) 1985-12-31
PL142890B1 (en) 1987-12-31
GB2139892B (en) 1987-04-23
GB2139892A (en) 1984-11-21
CH658190A5 (de) 1986-10-31
DK247284A (da) 1984-11-22
DE3477733D1 (en) 1989-05-24
NZ208214A (en) 1986-10-08
SG36089G (en) 1989-10-13
AU564263B2 (en) 1987-08-06
EP0126379B1 (de) 1989-04-19
FR2550092A1 (fr) 1985-02-08
EP0126379A3 (en) 1986-07-09
HU193287B (en) 1987-09-28
AU2806084A (en) 1984-11-22
KE3889A (en) 1989-09-01
PT78611B (en) 1986-07-15
IT8421013A0 (it) 1984-05-18
DK163278B (da) 1992-02-17
DK247284D0 (da) 1984-05-17
AT390879B (de) 1990-07-10
FI82376B (fi) 1990-11-30
ATE42198T1 (de) 1989-05-15
EP0126379A2 (de) 1984-11-28
PL247744A1 (en) 1985-11-05
DE3318649A1 (de) 1984-11-22
ES8505817A1 (es) 1985-06-16
HUT34690A (en) 1985-04-28
IL71871A (en) 1987-07-31
IT1218848B (it) 1990-04-24
GB8412820D0 (en) 1984-06-27
JPS59222475A (ja) 1984-12-14
CA1228550A (en) 1987-10-27
ES532515A0 (es) 1985-06-16
NO164817B (no) 1990-08-13
FR2550092B1 (fr) 1987-11-20
ATA164884A (de) 1990-01-15
FI82376C (fi) 1991-03-11
FI841995A (fi) 1984-11-22
DD222495A5 (de) 1985-05-22
BE899691A (fr) 1984-11-19
PH21989A (en) 1988-05-02
PT78611A (en) 1984-06-01
IL71871A0 (en) 1984-09-30
CS250663B2 (en) 1987-05-14

Similar Documents

Publication Publication Date Title
DE3477733D1 (en) Two-phase formulation
PT84786A (en) Process for the preparation of pharmaceutical formulations of acid labile substances for oral use
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
ATE82118T1 (de) Feste und poroese einheitsform, enthaltend mikropartikel und/oder nanopartikel und verfahren zu ihrer herstellung.
GR3001284T3 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
NZ225950A (en) Calcium citrate malate in the molar ratio of 6:2:3; pharmaceutical compositions
PT84041A (en) Process for the preparation of optically pure s-(-)-1-propyl-2:,6:-pipecoloxylidide hydrochloride monohydrate and of pharmaceutical compositions containing the same
SE8400723L (sv) Farmaceutisk komposition
DE3266072D1 (en) Method for the oral administration of substances in the form of liposomes, and relative pharmaceutical compositions
JPS6422A (en) Prophylactic and remedy for hypocalcemia and bone catabolism